drugset

drugset / Trial / NCT05718557

Study of PYX-106 in Solid Tumors

NCT05718557 ↗

Phase 1 Active not recruiting 47 enrolled Pyxis Oncology, Inc

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.

Timeline

Start: 2023-05-23
Primary completion: 2026-05
Completion: 2026-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALDASTOTUG	Monoclonal antibody	—	Intravenous

Indications